Loyal Dog Longevity Drugs: FDA Status of LOY-001, LOY-002 & LOY-003

Dr. Lucas Bennett

Patify Health & Science Writer

Loyal Dog Longevity Drugs: FDA Status of LOY-001, LOY-002 & LOY-003

Updated September 19, 2026 · Regulatory status, eligibility, price and evidence guide

Short answer: As of September 19, 2026, LOY-001, LOY-002 and LOY-003 are still investigational and are not FDA-approved or commercially available. LOY-002 is the most advanced: the FDA has accepted its Reasonable Expectation of Effectiveness (RXE) and Target Animal Safety (TAS) sections, while manufacturing/CMC remains in progress. LOY-001 received RXE in 2023. LOY-003 received RXE on September 16, 2026. None of these milestones proves that a Loyal drug extends an individual dog's life, and no final retail price has been announced.

Current FDA Status — September 19, 2026

What Does “Expanded Conditional Approval” Actually Mean?

The FDA Center for Veterinary Medicine uses expanded conditional approval for certain animal drugs addressing serious conditions or unmet health needs when definitive effectiveness studies are unusually complex or difficult. A conditionally approved animal drug must meet the FDA's safety and manufacturing standards, but instead of already having the “substantial evidence of effectiveness” required for full approval, it can initially rely on a reasonable expectation of effectiveness.

If a drug receives conditional approval, it may be legally marketed for one year at a time, with annual renewals possible for a total of up to five years while the sponsor gathers the remaining effectiveness evidence needed for full approval. That distinction is important for longevity medicines because proving a lifespan effect requires years of follow-up.

LOY-002: Why It Is Currently the Closest to Market

LOY-002 is Loyal's lead senior-dog program. Loyal's current product page states that it is intended for dogs 10 years or older and at least 14 lb. The company says the drug aims to improve metabolic health by increasing insulin sensitivity and lowering circulating insulin.

In February 2025, Loyal announced that the FDA accepted the LOY-002 RXE section. In December 2025, the FDA accepted its Target Animal Safety package. Loyal says that safety submission included a standard target-animal study plus field safety data from roughly 400 senior dogs in the STAY study. The remaining major technical section is CMC — chemistry, manufacturing and controls.

The STAY Study: What It Can — and Cannot — Tell Us Yet

STAY is Loyal's pivotal, randomized, double-blinded, placebo-controlled effectiveness study for LOY-002. Loyal currently reports 1,300+ participating senior dogs across 70 veterinary practices, and the study is fully enrolled. That means owners should not rely on older articles telling them they can still enroll a dog in STAY.

The study is designed to compare lifespan, quality of life and frailty-related outcomes between dogs receiving LOY-002 and placebo. Loyal has previously estimated that the full effectiveness study will run for years; its regulatory explainer says the pivotal dataset needed for full approval is expected around 2029.

No completed STAY result currently shows that LOY-002 adds a specific number of months or years to a dog's life. Statements such as “about one extra year” were public hopes or projections, not a final randomized trial result.

LOY-001 and LOY-003: The Large-Dog Programs

Large and giant dogs tend to have shorter average lifespans than smaller dogs. Loyal is developing LOY-001 and LOY-003 around the hypothesis that sustained growth-hormone and IGF-1 signaling contributes to this size-longevity relationship.

LOY-001 is intended for dogs aged at least 7 years and weighing at least 40 lb. It is designed as a long-acting veterinary injection. Its RXE technical section was accepted in 2023, which Loyal described as the first FDA acceptance of a regulatory path for lifespan extension as a drug indication.

LOY-003 is intended for dogs aged at least 5 years and weighing at least 60 lb. On September 16, 2026, Loyal announced that FDA accepted its RXE section. This made RXE complete across all three Loyal longevity programs. However, LOY-003 still requires the remaining safety and manufacturing work before it could receive expanded conditional approval.

Is the IGF-1 Explanation Proven?

There is strong evidence that dog body size is associated with lifespan and that the GH/IGF-1 pathway is biologically related to body size and aging. Loyal's current materials say LOY-001 and LOY-003 are intended to address GH/IGF-1 over-expression in large dogs.

However, the commercial drug candidates' active pharmaceutical ingredients remain confidential, according to Loyal. Owners should therefore be cautious with articles claiming to know the exact molecule, exact dose, exact downstream cancer effect or a detailed mechanism beyond what Loyal has publicly disclosed.

How Much Will LOY-001, LOY-002 or LOY-003 Cost?

There is no verified final retail price as of September 19, 2026. Loyal's current owner and product pages do not publish a list price. Earlier public comments from company leadership suggested the company was aiming for a broadly accessible monthly cost and discussed pricing in “double digits per month,” but that is not the same as a final veterinary retail price.

If a Loyal drug is approved, an owner's true cost could include the medication itself, veterinary examination or dispensing fees, and any monitoring required by the final label. Those details cannot be calculated reliably before approval.

Does the FDA Think These Drugs Definitely Work?

No. FDA acceptance of an RXE section is meaningful, but it is deliberately a lower effectiveness threshold than full approval. The FDA's own explanation says a conditionally approved drug has not yet met the effectiveness standard required for full approval; it instead has a reasonable expectation of effectiveness while definitive data are collected.

For LOY-002, the STAY trial is intended to provide the pivotal lifespan evidence needed for full approval. Until those data are complete and analyzed, no one should promise that the drug will add one year, two years or any specific amount of time to an individual dog's life.

What Do We Know About Safety?

LOY-002 is the only program for which Loyal has announced FDA acceptance of a complete Target Animal Safety technical section. Loyal says its safety package included studies at multiples of the expected dose and field safety data from senior companion dogs, and that the FDA accepted that section in December 2025.

That is an important regulatory milestone, but a public FDA-approved label and Freedom of Information summary are not yet available because the product itself has not been approved. Therefore, this guide does not publish a definitive side-effect list, contraindication list, drug-interaction list or monitoring protocol.

For LOY-001 and LOY-003, Loyal says full safety data will be submitted as part of their expanded conditional approval applications. Until that work is accepted and disclosed, claims such as “only mild injection-site reactions” or specific long-term safety guarantees are premature.

What Should You Ask Your Veterinarian Today?

Because none of the products is currently available, there is no evidence-based pre-prescription bloodwork checklist yet. Rather than ordering IGF-1 tests or special imaging because of internet articles, focus on established senior-dog preventive care.

• Is my dog's current weight, body condition and muscle condition appropriate?
• Is my dog due for age-appropriate bloodwork, urinalysis, dental care or other senior screening?
• Which existing diseases or medications are most important to manage now?
• What evidence-based steps can preserve mobility, lean muscle, cognition and quality of life?
• If a Loyal drug receives FDA approval, would my dog's age and weight potentially match the label?

What Changed Since the Original April 2026 Version?

Frequently Asked Questions

Senior Dog Records · Weight Trends · Medication History

Keep your dog's current health information organized so future treatment decisions are based on a complete veterinary history.

Download Patify